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S U M M A R Y
Objectives: Carbapenems are ﬁrst-line agents for severe infections with extended-spectrum beta-
lactamase (ESBL)-producing bacteria. The use of carbapenems, however, is associated with the
emergence of resistant organisms. We investigated the effects of empirical therapy with non-
carbapenems on urinary tract infections (UTIs) with ESBL-producing Enterobacteriaceae in a hospital
where antimicrobial stewardship has been established.
Methods: This retrospective chart review was undertaken at a tertiary care hospital where antimicrobial
stewardship and restriction of carbapenems has been established. Patients with a UTI with ESBL-
producing Enterobacteriaceae were stratiﬁed into susceptible and non-susceptible therapy groups
according to the susceptibility of the causative organism to the initial antimicrobial therapy. Outcome
measures were the duration of antimicrobial therapy, 14-day mortality, infection-related mortality, and
clinical cure.
Results: Of 90 patients, 30 (33.3%) exhibited susceptible therapy. However, no signiﬁcant difference was
observed in the duration of antimicrobial therapy, 14-day mortality, infection-related mortality, or
clinical cure between the susceptible and non-susceptible groups. Multivariate analyses revealed that
the independent risk factor for 14-day morality was the use of immunosuppressive agents (odds ratio
5.23, 95% conﬁdence interval 1.26–24.04; p = 0.023).
Conclusions: Non-carbapenem therapy against UTIs with ESBL-producing Enterobacteriaceae does not
pose a signiﬁcant risk to patients who are not taking immunosuppressive agents.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Extended-spectrum beta-lactamase (ESBL)-producing Enterobac-
teriaceae have emerged and pose a signiﬁcant threat not only to
hospitalized patients, but also in the community setting.1,2 The
markedincreaseinurinarytractinfections(UTIs)withESBL-producing
Enterobacteriaceae  in the community greatly limits adequate antimi-
crobial therapy.3,4 Although carbapenems are recommended as the
agents of last resort for the treatment of infections with ESBL-
producing Enterobacteriaceae,2,5 the increase in carbapenem use has
resulted in the emergence of carbapenem-resistant Enterobacteriaceae* Corresponding author. Tel.: +81 3 3353 1211; fax: +81 3 3353 2502.
E-mail address: takanori.asakura@gmail.com (T. Asakura).
http://dx.doi.org/10.1016/j.ijid.2014.08.018
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).(CRE).6 As CRE spread, the treatment of infections with these
organisms will become more difﬁcult.5 Non-carbapenems that have
in vitro activity against ESBL-producing Enterobacteriaceae would be
an option to suppress the emergence of CRE,7 but evidence of their
efﬁcacy for UTIs with ESBL-producing Enterobacteriaceae is very
limited.4,8 A major concern regarding non-carbapenems is the
unfavourable effect of inadequate antimicrobial therapy on the
outcome of high-risk patients.9 However, comparison of non-
carbapenems with carbapenems in randomized controlled trials,
which would provide robust evidence, is not feasible in settings where
antimicrobial stewardship has been established and carbapenems
have been restricted.7
In this context, we need evidence of the efﬁcacy of non-
carbapenems against ESBL-producing Enterobacteriaceae in carba-
penem-restricted settings. The purpose of this study was tociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
T. Asakura et al. / International Journal of Infectious Diseases 29 (2014) 91–9592determine the efﬁcacy of empirical therapy with non-carbapenems
in patients with UTIs caused by ESBL-producing Enterobacteriaceae
in a Japanese tertiary care hospital where antimicrobial steward-
ship has been implemented.
2. Patients and methods
2.1. Setting, subjects, and data collection
A review of the admission charts was carried out at Asahi
General Hospital, a 989-bed tertiary care teaching hospital where
antimicrobial stewardship programs have been established. We
searched the hospital database for ESBL-producing Escherichia coli,
Klebsiella pneumoniae, and Proteus mirabilis in urine cultures from
April 2006 to December 2011. We included the ﬁrst episode of the
UTI in patients aged 18 years. We excluded patients complicated
with another infection during the course of the UTI. Patients were
stratiﬁed into susceptible and non-susceptible therapy groups
according to the susceptibility of the causative organism to the
initial antimicrobial therapy.
2.2. Deﬁnitions
We diagnosed UTI on the basis of the following previously
reported criteria:3,4 signs and symptoms related to the UTI (fever,
haematuria, irritative symptoms in the lower urinary tract, and
tenderness in the costovertebral angle), bacteriuria (>104 CFU/ml),
and pyuria without an infectious focus outside the urinary tract.
Patients with both uncomplicated and complicated UTIs were
included. In total, 328 patients with urine cultures positive for
ESBL-producing Enterobacteriaceae were enrolled for the 69-month
study period. Of these 328 patients, 238 were excluded (asymp-
tomatic bacteriuria, n = 127; recurrent UTI, n = 74; cystitis, n = 24;
epididymitis, n = 1; incomplete medical records, n = 12) (Figure 1).
Thus, 90 patients with UTIs were analysed. Among all 328 patients
with a urine culture positive for ESBL, no patient was diagnosed
with prostatitis. We excluded patients with cystitis because most
patients with cystitis, in contrast to those with UTIs, have a good
prognosis without any hard endpoints.
UTIs were classiﬁed as community-acquired, health care-
associated, or hospital-acquired in accordance with the published
criteria.10 Empirical antimicrobial therapy was considered to be
susceptible if the therapy, administered within 24 h after the
acquisition of the urine culture sample, included at least one
antimicrobial that was effective in vitro against the causativeFigure 1. Patientmicroorganisms and if the dose and route of administration
conformed to current medical standards.9 According to the
2011 Clinical and Laboratory Standards Institute (CLSI) criteria,11
ESBL-producing Enterobacteriaceae susceptible to cephalosporins
other than cephamycin are categorized as non-susceptible.
Otherwise, therapy was considered non-susceptible. Prognostic
comorbidity was evaluated according to the Charlson comorbidity
index.12 Severe sepsis and septic shock were deﬁned according to
the American College of Chest Physicians/Society of Critical Care
Medicine Consensus Conference.13
2.3. Outcome measures
Outcome measures were the duration of antimicrobial therapy,
14-day mortality, infection-related mortality, and clinical cure.
Clinical cure was deﬁned as being alive with resolution of all
baseline symptoms 4 weeks after completion of therapy.14
2.4. Microbiological tests
ESBL-producing isolates were conﬁrmed with the BD Phoenix
System (Nippon Becton Dickinson Co., Ltd, Tokyo, Japan). Resis-
tance or susceptibility was determined by broth microdilution
according to the criteria established by the CLSI.11 ESBL production
was evaluated by a procedure described in the CLSI guidelines.11
2.5. Statistical analyses
Statistical analyses were carried out with JMP v10.0 (SAS
Institute Japan Ltd, Tokyo, Japan). The t-test was used to compare
the means of continuous variables between the two groups. The
Chi-square test or Fisher’s exact test was used to compare
dichotomous variables. To identify the independent risk factors
for mortality, variables with a signiﬁcant association with
mortality on univariate analysis were entered into a logistic
regression model for multivariate analysis. All p-values were two-
tailed; p < 0.05 was considered signiﬁcant.
3. Results
3.1. Patient characteristics
The mean age of the patients was 74.1  13.9 years; 46 (51.1%)
were women (Table 1). Thirty patients (33.3%) received susceptible
antimicrobial therapy, whereas 60 patients (66.7%) received enrolment.
Table 1
Demographic characteristics of the patientsa
Characteristics Susceptible
empirical
therapy (n = 30)
Non-susceptible
empirical
therapy (n = 60)
p-Value
Males 17 (56.7) 27 (45.0) 0.372
Age, years 71  15, 36–93 76  13, 37–97 0.172
Charlson comorbidity index 3.5  2.0 4.2  2.7 0.310
Ward
Internal medicine 24 (80.0) 42 (70.0)
Surgical 4 (13.3) 8 (13.3)
Urology 2 (6.7) 10 (16.7) 0.412
Underlying disease
Cerebrovascular disorder 13 (43.3) 25 (41.7) 1.000
Chronic kidney disease 8 (26.7) 17 (28.3) 1.000
Connective tissue disease 3 (10.0) 6 (10.0) 1.000
Congestive heart failure 4 (13.3) 6 (10.0) 0.726
Diabetes mellitus 5 (16.7) 21 (35.0) 0.087
Obstructive uropathy 11 (36.7) 14 (23.3) 0.216
Malignancy 9 (30.0) 17 (28.3) 1.000
Comorbid condition
Bacteraemia 7 (25.0) 15 (25.0) 1.000
Colonized ESBL 7 (23.3) 7 (11.7) 0.216
Central venous catheter 1 (3.3) 2 (3.3) 1.000
UTI within the last 6 months 10 (33.3) 24 (40.0) 0.647
Admission for 14 days 26 (86.7) 40 (66.7) 0.048b
Immunosuppressive agents 9 (30.0) 14 (23.3) 0.609
Severe sepsis or septic shock 7 (23.3) 5 (8.3) 0.096
Urinary catheter 9 (30.0) 21 (35.0) 0.813
Infection type
Community-acquired 3 (10.0) 6 (10.0)
Health care-associated 3 (10.0) 19 (31.7)
Nosocomial 24 (80.0) 35 (58.3) 0.072
Microorganism
Escherichia coli 19 (63.3) 32 (53.3)
Proteus mirabilis 8 (26.7) 19 (31.7)
Klebsiella pneumoniae 3 (10.0) 9 (15.0) 0.639
ESBL, extended-spectrum beta-lactamase; UTI, urinary tract infection; SD, standard
deviation.
a Data are shown as the mean  SD, mean  SD with range, or n (%), as appropriate.
b Signiﬁcant.
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marginally higher in the susceptible therapy group than in the non-
susceptible group. Other characteristics did not show signiﬁcant
differences.
3.2. Antimicrobial susceptibility
Table 2 shows the antimicrobial susceptibilities of the 90 ESBL-
producing bacteria isolates. E. coli, P. mirabilis, and K. pneumoniae
comprised 51 (56.7%), 27 (30.0%), and 12 (13.3%) isolates,
respectively. Almost all bacteria were susceptible to amikacin,Table 2
Antimicrobial susceptibility of urine isolates of ESBL-producing Enterobacteriaceaea
Antimicrobial agent Escherichia coli 
n = 51 
Amikacin 51 (100.0) 
Aztreonam 6 (11.8) 
Cefepime 2 (3.9) 
Cefotaxime 2 (3.9) 
Ceftazidime 21 (41.2) 
Cefmetazole 49 (96.1) 
Gentamicin 32 (62.7) 
Levoﬂoxacin 23 (45.1) 
Minocycline 27 (52.9) 
Imipenem 50 (98.0) 
Piperacillin–tazobactam 44 (86.3) 
Trimethoprim–sulfamethoxazole 27 (52.9) 
ESBL, extended-spectrum beta-lactamase.
a Data are shown as n (%).cefmetazole, and imipenem. Resistance to piperacillin–tazobactam
and trimethoprim–sulfamethoxazole was substantially more
common among E. coli and K. pneumoniae than among P. mirabilis
isolates. Other agents were ineffective for all bacteria.
3.3. Empirical antimicrobial therapy
Table 3 shows the initial empirical antimicrobial therapy in the
susceptible and non-susceptible therapy groups. We included
seven patients treated with carbapenems as a ﬁrst-line agent, ﬁve
as monotherapy and two as combination therapy, in the
susceptible therapy group. These numbers are small because
antimicrobial stewardship has been established in the hospital and
the administration of carbapenems is restricted to critically ill
patients suspected of having infections caused by ESBL-producing
bacteria. Sixty patients received non-susceptible therapy because
of resistance to antimicrobials (cephalosporins, n = 41; penicillin,
n = 9; quinolones, n = 4; combination therapy, n = 5; no therapy,
n = 1). In 12 of the 60 patients (20.0%) in the non-susceptible
therapy group, carbapenems were administered after 3.83  1.80
(mean  standard deviation) days. Fourteen (23.3%) patients were
treated with antimicrobials other than carbapenems after 4.64  2.67
(mean  standard deviation) days (cefmetazole, n = 5; aminoglyco-
side, n = 4; trimethoprim–sulfamethoxazole, n = 2; piperacillin–
tazobactam, n = 2; levoﬂoxacin, n = 1). The remaining 34 (56.7%)
patients were treated with only non-susceptible antimicrobials. Of
these patients, 30 showed substantial improvement in their course
and four patients died (one of subarachnoid haemorrhage, one of
heart failure, one of end-stage gastric cancer, and one of aspiration
pneumonia after improvement of the UTI).
3.4. Outcome measures
Table 4 shows the outcome measures. No signiﬁcant
differences were observed in the duration of antimicrobial
therapy, 14-day mortality, infection-related mortality, or clinical
cure between the two groups. In the susceptible therapy group,
ﬁve patients died with no clinical cure (four of UTI and one of
gastric cancer). In the non-susceptible therapy group, seven
patients died with no clinical cure (four of UTI, one of
subarachnoid haemorrhage, one of congestive heart failure,
and one of interstitial pneumonia).
Table 5 shows the characteristics of the patients in the
susceptible and non-susceptible therapy groups who died. Six of
the eight patients who died of UTI received corticosteroids,
whereas none of the four patients who died of other causes
received corticosteroids or other immunosuppressive agents.Proteus mirabilis Klebsiella pneumoniae
n = 27 n = 12
27 (100.0) 12 (100.0)
16 (59.3) 3 (25.0)
0 (0.0) 1 (8.3)
0 (0.0) 2 (16.7)
21 (77.8) 5 (41.7)
27 (100.0) 12 (100.0)
15 (55.6) 5 (41.7)
4 (14.8) 9 (75.0)
0 (0.0) 0 (0.0)
27 (100.0) 12 (100.0)
27 (100.0) 6 (50.0)
25 (92.6) 4 (33.3)
Table 3
Initial empirical therapy in susceptible and non-susceptible groupsa,b
Initial therapy Escherichia coli Proteus mirabilis Klebsiella pneumoniae Total
n = 51 n = 27 n = 12 n = 90
Susceptible group 19 (37.3) 8 (29.6) 3 (25.0) 30 (33.3)
Aminoglycosides 0 (0.0) 0 (0.0) 1 (8.3) 1 (1.1)
Carbapenem 3 (5.9) 2 (7.4) 0 (0.0) 5 (5.6)
Cephamycin 3 (5.9) 3 (11.1) 1 (8.3) 7 (7.8)
Penicillins 6 (11.8) 1 (3.7) 0 (0.0) 7 (7.8)
Quinolones 2 (3.9) 0 (0.0) 1 (8.3) 3 (3.3)
Trimethoprim–sulfamethoxazole 0 (0.0) 2 (7.4) 0 (0.0) 2 (2.2)
Combination therapy 5 (9.8) 0 (0.0) 0 (0.0) 5 (5.6)
Non-susceptible group 32 (62.7) 19 (70.4) 9 (75.0) 60 (66.7)
Cephalosporins 20 (39.2) 14 (51.9) 7 (58.3) 41 (45.6)
Penicillins 5 (9.8) 3 (11.1) 1 (8.3) 9 (10.0)
Quinolones 3 (5.9) 1 (3.7) 0 (0.0) 4 (4.4)
Combination therapy 4 (7.8) 0 (0.0) 1 (8.3) 5 (5.6)
No therapy 0 (0.0) 1 (3.7) 0 (0.0) 1 (1.1)
a Empirical antimicrobial therapy was considered to be ‘susceptible’ if the therapy, administered within 24 h after the acquisition of the urine culture sample, included at
least one antibiotic that was effective in vitro against the causative microorganisms and if the dose and route of administration conformed to current medical standards.
Microorganisms susceptible to cephalosporins other than cephamycin were categorized as non-susceptible. Otherwise, the therapy was considered to be ‘non-susceptible’.
b Data are shown as n (%).
Table 4
Outcome measures in susceptible and non-susceptible groupsa,b
Outcome measure Susceptible therapy group Non-susceptible therapy group p-Value
n = 30 n = 60
Duration of antimicrobial therapy, days, mean (SD) 11.7 (6.3) 12.2 (4.4) 0.426
14-day mortality 5 (16.7) 5 (8.3) 0.292
Infection-related mortality 4 (13.3) 4 (6.7) 0.433
Clinical cure 25 (83.3) 53 (88.3) 0.525
SD, standard deviation.
a Empirical antimicrobial therapy was considered to be ‘susceptible’ if the therapy, administered within 24 h after the acquisition of the urine culture sample, included at
least one antibiotic that was effective in vitro against the causative microorganisms and if the dose and route of administration conformed to current medical standards.
Microorganisms susceptible to cephalosporins other than cephamycin were categorized as non-susceptible. Otherwise, the therapy was considered to be ‘non-susceptible’.
b Data are shown as n (%), unless otherwise indicated.
Table 5
Characteristics of patients who died in the susceptible (patients 1–5) and non-susceptible (patients 6–12) therapy groups
No. Age,
years
Sex Microorganisma Underlying disease Severe sepsis or
septic shock
Immunosuppressive
agents
Antimicrobials Date of
death, day
Cause of death
1 62 F E. coli Lymphoma Septic shock Steroid PIP/TAZ, VCM 2 UTI
2 80 M E. coli CKD, gastric cancer None None CMZ 12 Gastric cancer
3 62 F E. coli Interstitial pneumonia None None MEPM 3 UTI
4 84 F E. coli Vasculitis Septic shock Steroid MEPM, VCM, TOB 6 UTI
5 90 F E. coli CHF, CKD Septic shock Steroid MEPM, VCM 5 UTI
6 93 F E. coli DM, CKD None None ABPC/SBT 29 Aspiration
pneumonia
7 91 F E. coli SAH None None CTX 8 SAH
8 73 M E. coli CKD, rectal cancer, nephrostomy None Steroid CPFX 6 UTI
9 80 F K. pneumoniae DM, gastric cancer, nephrostomy None None CAZ, GM 14 UTI
10 66 M K. pneumoniae CKD, lymphoma None None CTX 23 CHF
11 86 F P. mirabilis Bullous pemphigoid None Steroid ABPC, CTRX, GM 4 UTI
12 80 M P. mirabilis CHF, DM, interstitial pneumonia None Steroid CTX 9 UTI
ABPC/SBT, ampicillin/sulbactam; CAZ, ceftazidime; CHF, congestive heart failure; CKD, chronic kidney disease; CMZ, cefmetazole; CPFX, ciproﬂoxacin; CTRX, ceftriaxone;
CTX, cefotaxime; DM, diabetes mellitus; F, female; GM, gentamicin; M, male; MEPM, meropenem; PIP/TAZ, piperacillin/tazobactam; SAH, subarachnoid haemorrhage; TOB,
tobramycin; UTI, urinary tract infection; VCM, vancomycin.
a Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis.
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that the use of immunosuppressive agents was an independent
risk factor for 14-day mortality, but that non-susceptible empirical
therapy was not (Table 6).
4. Discussion
Our study provides evidence that in patients with UTIs with
ESBL-producing Enterobacteriaceae, the efﬁcacy of non-susceptibleempirical therapy with non-carbapenems is comparable to that
of susceptible therapy. We observed no difference in the
duration of antimicrobial therapy, 14-day mortality, infection-
related mortality, or clinical cure between the susceptible and
non-susceptible therapy groups. Non-susceptible therapy was
not a risk factor for 14-day mortality. Although the difference
was not statistically signiﬁcant, the susceptible therapy group
showed higher mortality than the non-susceptible therapy
group. This probably occurred because carbapenem-treated
Table 6
Risk factors for 14-day mortality
Variables Univariate analysis Multivariate analysis
OR (95% CI) OR (95% CI) p-Value
Non-susceptible empirical therapya 2.20 (0.58–8.29) 1.57 (0.31–7.28) 0.569
Immunosuppressive agents 5.56 (1.41–21.96) 5.23 (1.26–24.04) 0.023b
Severe sepsis or septic shock 3.38 (0.74–15.46) 3.16 (0.45–19.30) 0.231
Malignancy 1.76 (0.45–6.83) 2.40 (0.47–12.60) 0.286
Age 70 years 1.71 (0.34–8.68) 2.68 (0.48–24.51) 0.278
OR, odds ratio; 95% CI, 95% conﬁdence interval.
a Empirical antimicrobial therapy was considered to be ‘susceptible’ if the therapy, administered within 24 h after the acquisition of the urine culture sample, included at
least one antibiotic that was effective in vitro against the causative microorganisms and if the dose and route of administration conformed to current medical standards.
Microorganisms susceptible to cephalosporins other than cephamycin were categorized as non-susceptible. Otherwise, the therapy was considered to be ‘non-susceptible’.
b Signiﬁcant.
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susceptible therapy group.
Although carbapenem restriction to suppress the emergence of
CRE7 raises other concerns regarding the efﬁcacy of non-
carbapenems, particularly if the organism is resistant, antimicro-
bial resistance does not adversely affect the outcome for patients
with UTIs.15 The infection site strongly inﬂuences the ability of
susceptible therapy to reduce mortality among patients with
infections caused by ESBL-producing Enterobacteriaceae. Non-
susceptible therapy is a risk factor for mortality only among non-
UTIs.16–18
In addition to the susceptibility of empirical therapy, we
found immunosuppressive agents to be an independent risk
factor for 14-day mortality. Studies have shown malignancy5 and
older age15,18 to be risk factors associated with increased
mortality in patients with infections caused by ESBL-producing
Enterobacteriaceae. The use of immunosuppressive agents, espe-
cially corticosteroids, is generally considered to be a risk factor for
infection,19 as shown in our study. In patients with bloodstream
infections with ESBL-producing Enterobacteriaceae,20 the use of
immunosuppressive agents showed a marginal association with
mortality.
Our study has several potential limitations. First, the study
design, a retrospective review of hospital admission charts, made
it difﬁcult to eliminate unknown confounding factors that might
have been unequally distributed between the two study groups
and affected the evaluation of treatment efﬁcacy. Second, the
small number of patients underpowered the study and made
some subgroup analyses impossible to perform. Some outcomes
may not be statistically signiﬁcant because of the small number
of patients. Third, the results of our study are not applicable to
critically ill patients because the number of patients included
with severe sepsis or septic shock was very small. Finally, we did
not identify the factors that affected the decisions of the
attending physicians regarding the choice of antimicrobial
therapy. These unidentiﬁed factors might have caused bias in
our results.
In conclusion, empirical therapy with non-carbapenems is an
effective method by which to reduce the risk of development of
carbapenem-resistant organisms in patients with UTIs caused by
ESBL-producing Enterobacteriaceae without immunosuppressive
agents. Considering the emergence of CRE, carbapenems should be
limited to patients with severe non-UTIs caused by ESBL-
producing Enterobacteriaceae.
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